Where Holann Is Investing, AI to Focus on Pharmaceuticals, and SK Hynix's Record-Breaking Offering
This Week's Highlights on Oninvest
Hollann never strays from his image as a down-to-earth guy who spends his time in provincial Brune, even when he's flying in a private jet and engaging in tax optimization. Photo: Lars Baron/Getty Images Sport
It turned out that the sense of calm following the resolution of the military crisis between the U.S. and Iran was premature. This week, the truce came to an end—at least according to Donald Trump’s assessment of the situation. The sides resumed attacks on each other, and the situation in the Strait of Hormuz returned to a state of full-scale armed conflict—traffic has effectively come to a standstill. Oil prices began to rise again, with the price of a barrel of Brent briefly reaching $80.
The stock market, however, reacted less sharply: investors took advantage of the dip that occurred immediately after the escalation to buy. How do strategists explain this? Some say that periodic flare-ups of tension are already priced in, while others say that the main focus right now is the corporate earnings season, which begins next week.
What else were we keeping an eye on?
One of the week’s most significant events was the record-breaking U.S. IPO of South Korean memory manufacturer SK Hynix. Its American Depositary Receipts raised $26.5 billion—more than any other foreign company has ever raised. Why has this “quiet and uninteresting” segment of the semiconductor market become one of the “hottest” bets on the AI boom? How did the company build its position over 14 years—despite skepticism and criticism? And what do attractive suitors and packed hotels have to do with it? We’ve covered it all here.
Incidentally, it was memory manufacturers that generated the most profit for billionaire David Tepper’s hedge fund, Appaloosa Management—in the first half of the year, the fund posted a return of 32% thanks to investments in Micron, Samsung, SK Hynix, and other players in this sector.
But Bill Eckman isn't investing in Micron. They explained how and which companies he chooses: "We act as if the stock market could close tomorrow for an entire decade."
Interestingly, SK Hynix’s IPO even overshadowed the recent IPO headline-maker—SpaceX: Elon Musk’s company’s accelerated inclusion in the Nasdaq-100 index was called a “side story.” Leading Wall Street analysts, however, are almost unanimously expecting further growth.
Onside, not offside
We’re looking for investment inspiration not only from Wall Street’s big players: we found out where one of the top scorers of the 2026 World Cup—Norwegian star Erling Haaland, who ranks among the top 5 highest-paid players in the tournament—has invested his money. He plays like a Viking—but how does he make his money?
Dr. Claude—Who Will Develop Medicines Tomorrow?
Anthropic, OpenAI, and other AI companies are entering the pharmaceutical industry, promising to accelerate the development of new drugs—just as the industry faces its biggest patent cliff in decades. But is artificial intelligence truly capable of revolutionizing the pharmaceutical market and transforming its economics, or is this just a tall tale ahead of the AI giants’ IPOs? Roman Kutuzov got to the bottom of it.
By the way, we’ve decided not only to look to the future but also to study the lessons of the past: Our financial guru researcher, Anna Krasnova, is launching a history column and will start by telling us about the “Witch of Wall Street,” Hetty Green, who built a financial empire in the early 20th century. Investment lessons from the “Buffett in a skirt”—check out Oninvest on Sunday!
And be sure to follow us on Google News—it’s an easy way to support our editorial team and make sure you don’t miss the most important news and analysis.
This article was AI-translated and verified by a human editor
